Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Etelcalcetide (Parsabiv) vs Icatibant (Firazyr)
An educational, source-based comparison of Etelcalcetide (Parsabiv) and Icatibant (Firazyr) — how each peptide works, what it's researched for, and what to know before going deeper.
Calcimimetic peptide for secondary hyperparathyroidism on hemodialysis.
Synthetic D-amino-acid peptide that binds the calcium-sensing receptor on parathyroid chief cells, increasing its sensitivity to extracellular calcium and lowering PTH secretion.
- Secondary hyperparathyroidism in adults on chronic hemodialysis
- • FDA-approved.
- • Hypocalcemia common; monitor calcium and avoid in low corrected calcium.
Bradykinin B2 receptor antagonist for hereditary angioedema attacks.
Synthetic decapeptide that competitively blocks the bradykinin B2 receptor, halting the vascular leak that drives HAE swelling attacks.
- Hereditary angioedema (acute attacks)
- • FDA-approved.
- • Injection-site reactions very common.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Etelcalcetide (Parsabiv) | Etelcalcetide vs cinacalcet | JAMA | 2017 | Non-inferior PTH reduction with IV administration. |
| Icatibant (Firazyr) | FAST-3 trial | Annals of Allergy | 2011 | Faster symptom relief vs placebo in HAE attacks. |
Side-effect & safety grid
- FDA-approved.
- Hypocalcemia common; monitor calcium and avoid in low corrected calcium.
- FDA-approved.
- Injection-site reactions very common.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Etelcalcetide (Parsabiv) vs Icatibant (Firazyr) — Key differences
- Class: Etelcalcetide (Parsabiv) is classified as Calcium-Sensing Receptor Agonist · Endocrine, while Icatibant (Firazyr) is Bradykinin Antagonist · Immunology.
- Primary research focus: Etelcalcetide (Parsabiv) — secondary hyperparathyroidism in adults on chronic hemodialysis; Icatibant (Firazyr) — hereditary angioedema (acute attacks).
- Tag: FDA-Approved · Endocrine vs FDA-Approved · Rare Disease.